Efficacy of cytotoxic chemotherapy in recurrent/metastatic adenoid cystic carcinoma (ACC).

• DOI: 10.1200/jco.2024.42.16_suppl.6111
• Publication Date: 2024-08-05T19:41:52Z
• Authors: Michael Wotman; Camilla Oliveira ...; Flavia Bonini; Matthew Sawyer; Kaiwen Wang; Eduardo Andreazza...; Luana Guimaraes d...; Renata Ferrarotto
• Keywords: Adenoid Cystic Carcinoma

6111 Background: Despite aggressive local therapy, many ACC patients (~50%) develop recurrent and/or metastatic (R/M) disease. However, there is no standard of care or FDA-approved systemic therapy for this population. Based on small phase II trials, mostly including multiple salivary gland histologies, cytotoxic chemotherapy recommended symptomatic with high tumor burden, but its efficacy and impact survival in R/M remain unsubstantiated. Methods: A retrospective cohort study was conducted at MD Anderson Cancer Center an institutional database (N=769). Patients diagnosed treated single-agent combination palliative-intent were included. The primary endpoints overall response rate (ORR) disease control (DCR) per RECIST 1.1. Secondary median (mOS) progression-free (mPFS) the entire stratified by growth pattern (solid v non-solid), line (1 >2), regimen, stage diagnosis (M0 M1). Results: 48 out 115 who received evaluated RECIST.Median age 43.6 years. 56% male, 79% had M0 diagnosis, 67% minor tumors, 52% solid pattern, 31% non-solid 54% first-line chemotherapy. most common regimens Platinum/Vinorelbine (38%), Platinum/Taxane (27%) CAP (15%).The ORR DCR rates 12.5% 56.3% respectively; 6 partial response, 21 stable disease, progressive 20% 6.7% 73.3% respectively. mOS from 7 years (95% CI, 3.5-10.7). 16 months 10.8-24.5). There a significant difference between (10.8 24.1 months, p=0.015), not diagnosis. mPFS 4.3 2.8-6.3 months). (4.0 7.3 p=0.018), Conclusions: In largest to date real-world data ACC, outcomes lower than historical data. may vary other patient factors, which requires further investigation. Given low slow-growing volumetrics be better assess treatment benefit.